CD274 and sarcoma: The activity of ICIs in sarcomas is more challenging and only recently, in December 2022, atezolizumab (an anti-PD-L1 antibody) received FDA approval for advanced alveolar soft part sarcoma (ASPS), for which an overall response rate of 24% and a 42% duration of response over 12 months was observed (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-approval-atezolizumab-alveolar-soft-part-sarcoma accessed on 13 April 2023) (ClinicalTrials.gov Identifier: NCT03141684).